Search

everythinglearnresearchcommunity

for

Search:↓

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

MR antagonists may improve skin health and wound healing, especially in aging.

OXTR agonists may promote hair growth and be effective for treating hair loss.

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Aromoline and DRD4 are potential targets for osteoarthritis treatment.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

RORA may help regulate hair growth by affecting hair follicle stem cells.

R-spondins and their receptors help increase bone growth and may be used to treat bone loss diseases.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

SARMs work differently in tissues due to unique interactions and structures.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.

Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.

ROR2 is crucial for hair follicle stem cell maintenance and self-renewal.

Ruxolitinib treatment may cause eyelash growth.

Pexidartinib often causes liver issues and fatigue, especially in women.

Isoxazole 9 (ISX9) may help regrow hair by activating certain cell signals.

Hyaluronic acid microneedles help deliver minoxidil derivatives effectively for hair regrowth.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.

PXX is an effective and affordable photocatalyst for creating new chemical bonds in organic synthesis.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Targeting NCoR1 can help treat heart enlargement and dysfunction.

ERG increases SOX9, promoting prostate cancer growth and invasion.

Potassium channel openers help form elastic fibers in arteries and can treat elastin deficiency and hypertension.